CN101601741B

CN101601741B - Diuretic medicine

Info

Publication number: CN101601741B
Application number: CN2008100849338A
Authority: CN
Inventors: 刘玉珍; 刘墨林; 刘森林; 刘常林; 刘文林; 刘建国; 刘广林; 刘武林; 刘文平
Original assignee: Individual
Current assignee: Individual
Priority date: 2008-03-07
Filing date: 2008-03-07
Publication date: 2012-05-30
Anticipated expiration: 2028-03-07
Also published as: CN101601741A

Abstract

The invention relates to a diuretic medicine which uses natural animal and plant medical materials as main medicinal ingredients, has the efficacy of reducing fever, dredging stranguria, promoting blood circulation by removing blood stasis, promoting urination and freeing bi, is used for prostatitis and benign hyperplasia (uroschesis) and has favorable therapeutic action on downward damp-heat and congestion anesthesia diseases. The preparation method of the diuretic medicine comprises the following raw materials in percentage by weight: panax notoginseng: 7-14, leech: 3-9, cornu gorais powder: 2-6, scurfpea: 3-9, desmodium styracifolium: 10-25, Caulis Clematidis Armandii: 3-9, forsythia: 3-12, turtle shells: 10-30, atractylodes: 2-8 and radix cyathulae: 3-10 and is prepared into a preparation by a general oral dosage technology. The simple and convenient preparation is developed by extracting active ingredients of various medical materials according to the nature and flavor characteristics of the medical materials by a traditional Chinese medical science theory composition clinically proved for 50 years.

Description

Diuretic medicine

Technical field

It is that main medicinal ingredient is used to medicine of treating prostatitis, benign prostatic hyperplasia (difficulty in urination) and preparation method thereof that the thin urine of the present invention passes to natural animal and plant medical material.

Background technology

Prostatitis, benign prostatic hyperplasia (BPH) the property difficulty in urination are commonly encountered diseases, are again difficult treatments.Show according to epidemiology branch of international benign prostatic hyperplasia the 4th executive session of Advisory Board (1997.7.2 Paris) statistics; BPH is the modal urological diseases of elderly men; And increase year by year along with aged tendency of population, its sickness rate is obvious rising in recent years and becomes.In the U.S., the male nearly all has the BPH symptom more than 85 years old, and the old people more than 85 years old with 200 sides in 1980 increase to 2000 4,000,000, will reach 1,800 ten thousand or more to the year two thousand fifty, growth trend is very surprising.In Britain, the male senile patient in 75-84 year has increased by 70% in 18 years, and the male more than 85 years old has increased by 1 times in the phase at the same time, and wherein 30% has BPH to block symptom.In China, postmortem in 1936 report BPH rose to 30.5% in 6.6% to 1992 year, was the former 4 times.Therefore, the morbidity of BPH will be the health problem of the maximum that faces of All Countries among the current old people.The treatment of primary disease has 3 types at present.

Surgical result is good, and it is for removing prostatic hyperplasia morbidity condition of illness and the more effective Therapeutic Method of lower urinary tract obstruction, and the situation that the absolute indication of operation occurs is that it is unique solution.But more patient is in relative operative indication or non-operation indication.Though the improvement of operation greatly reduces its danger in recent years; But also non-being perfectly safe; Still have certain complication and sequela; Bigger prostatic hyperplasia is when carrying out urethra resection of prostate art (TURP), and as not accomplishing excision at 60 minutes with interior, it is dangerous to be the same with the open surgery treatment.The long-term effect of TURP, 20-25% is not satisfactory, still has urinary tract symptom: more than 10 years, 15-20% needs operation once more.Therefore, be in the gerontal patient of relative operative indication and non-operation indication, majority more is ready to accept other comparatively conservative Therapeutic Method, comprises interventional therapy or Drug therapy.

Interventional therapy is the novel therapies between operation and Drug therapy, and it has opened up new approach for the treatment of BPH.

Yet the indication that these treatments have is narrow, and the long-term effect that has is undesirable, but possibly become one of in the future main selectable treatment the development prospect that also has.

In fact, people more are contemplated for the more conservative treatment of selection, i.e. Drug therapy.But present Drug therapy neither be very good, and quality is respectively arranged.The A-receptor blocking agent can make the prostate smooth muscle loosening, reduces functional blocking, and is effective and fast, but can not stop prostate to continue hypertrophy, and certain cardiovascular and cerebrovascular vessel side effect is arranged; 5a-reductase inhibitor prostate always continues hypertrophy, and that continues possibly dwindle prostate, improves and blocks symptom, and side effect is little, but curative effect is also unsatisfactory.

Along with giving birth to improving constantly of words level, people have not satisfied existing medical level, and the quality and quantity of health care is had higher requirement.Therefore, the medicine of seeking new high-efficiency low-toxicity is very necessary.And Chinese medicine has formed the theoretic knowledge of own uniqueness aspect the treatment benign prostate hyperplasia, has accumulated rich experience, and Chinese medicine has caused attracting attention of common people with its curative effect that can make and the nontoxic superiority of low toxicity.Today of uphold nature therapy in the whole world, actively excavate traditional medicine precious legacy, research and develop with strong points, determined curative effect, the low Chinese patent drug of side effect, solve vast benign prostate hyperplasia patient's misery, beyond doubt a significant problem.Liu Molin professor further research on the precious treatment of his father old docter of TCM Liu Yu prostatic hyperplasia (difficulty in urination) basis; " diuretic medicine " developed in the clinical verification that went through 50 years front and back; Treatment prostatitis, benign prostatic hyperplasia (difficulty in urination) have been obtained gratifying curative effect, and have not been found any untoward reaction.

Summary of the invention

The objective of the invention is to propose to dredge the logical medicine that prostatitis, benign prostatic hyperplasia (difficulty in urination) is had good therapeutical effect of urine.

Medicine of the present invention is based on Chinese medicine to prostatitis, the pathogenetic understanding of benign prostatic hyperplasia (difficulty in urination) and Therapeutic Principle; With reference to the modern pharmacology achievement in research; The logical crude drug that closes function of clearing heat and freeing strangury, blood circulation promoting and blood stasis dispelling, diuresis that has that from clinical trial for many years, filters out is used the animal and plant Chinese crude drug; To prostatitis, benign prostatic hyperplasia (difficulty in urination) damp invasion of lower energizer, congestion retardance card extremely, therapeutical effect is preferably arranged.The present invention is according to the Traditional Chinese medical theory prescription, and according to the nature and flavor characteristics of each herbal medicine, extracts its effective ingredient, the preparation of the taking convenience that develops.

The present invention proposes diuretic medicine by medicament: Radix Notoginseng 7-14, Hirudo 3-9, Cornu Naemorhedi powder 2-6, Fructus Psoraleae 3-9, Herba Desmodii Styracifolii 10-25, Caulis Clematidis Armandii 3-9, Fructus Forsythiae 3-12, Carapax Trionycis 10-30, Rhizoma Atractylodis Macrocephalae 2-8, Radix Cyathulae 3-10 so that following raw material is formed and weight proportion is processed.

The preparation technology's method that the present invention proposes diuretic medicine is made up of following steps:

1, get the Rhizoma Atractylodis Macrocephalae, Fructus Forsythiae water vapour distillation volatile oil, volatile oil solution adds the beta-schardinger dextrin-inclusion, separates, and low-temperature vacuum drying is subsequent use;

2, Radix Notoginseng, Fructus Psoraleae are subsequent use with 70% alcohol reflux alcohol extract;

3, incorporate into after Carapax Trionycis elder generation water is carried 2 hours Hirudo, Herba Desmodii Styracifolii, Fructus Forsythiae, Caulis Clematidis Armandii, Radix Cyathulae again water carry 3 times, merge the water extract, concentrate, add 70% ethanol precipitation, filter, filtrating merges with the Radix Notoginseng alcohol extract, reclaims ethanol extract, it is subsequent use to be dried to dried cream;

4, dried cream and Cornu Naemorhedi powder, volatile oil inclusion complex mixed powder are broken into fine powder, and the abundant mixing of medicine is processed required medicament.

The pharmaceutical dosage form that the present invention proposes is a said peroral dosage form on the pharmaceutics.The pill (watered pill, honeyed pill, condensed water honeyed pill, drop pill) that can be raw material according to the invention process through conventional technology with corresponding excipient substance, tablet, capsule, granule, powder, unguentum, oral liquid etc.

Its consumption is per day for adults 2-6 gram.

The present invention proposes the diuretic medicine prescription and is characterised in that the medicament of being processed by the following raw material components change: former prescription Radix Notoginseng, Hirudo, Cornu Naemorhedi powder, Fructus Psoraleae, Herba Desmodii Styracifolii, Caulis Clematidis Armandii, Fructus Forsythiae, Carapax Trionycis, the Rhizoma Atractylodis Macrocephalae, Radix Cyathulae be totally 10 flavor components, increases or reduce the medicament that the 1-3 flavor is formed.

Pharmacodynamics test of the present invention:

Dredge capsule for urine purgation main pharmacodynamics research catalogue

(concrete testimonial material is waited to mend)

13-1 is to the influence of urogenital sinus implantation mice prostatic hyperplasia

13-2 is to the influence of experimental rat prostatic hyperplasia

13-3 influences the rat diuretic

1, to the influence of water load rat urine amount

2, the influence of Na+, K+, CI-in the water load rat urine

13-4 influences microcirculation of mouse auricle

13-5 is to influence acute, chronic inflammatory reaction

1, the influence of xylol induced mice auricle edema

2, the influence of mice capillary permeability

13-6 is to the influence of mice pain model

1, the influence of acetic acid induced mice pain

2, to the influence of mice hot plate method pain

The specific embodiment 1:

Get 4 parts of the Rhizoma Atractylodis Macrocephalaes, 4 parts of water vapour distillation volatile oil of Fructus Forsythiae by weight ratio, volatile oil solution adds the beta-schardinger dextrin-inclusion, separates, and low-temperature vacuum drying is subsequent use; 9 parts of Radix Notoginseng, 6 parts of Fructus Psoraleaes are subsequent use with the alcohol reflux alcohol extract with 70%; Incorporate into after 22 parts of first water of Carapax Trionycis are carried 2 hours 9 parts of 5 parts of Hirudos, 18 parts of Herba Desmodii Styracifolii, 8 parts of Fructus Forsythiaes, 7 parts of Caulis Clematidis Armandiis, Radix Cyathulae again water carry 3 times, merge the water extract, concentrate; Add 70% ethanol precipitation, filter, filtrating merges with the Radix Notoginseng alcohol extract; Reclaim ethanol extract, it is subsequent use to be dried to dried cream; Dried cream and Cornu Naemorhedi powder, volatile oil inclusion complex mixed powder are broken into fine powder, the abundant mixing of medicine, and above raw material is processed granule with corresponding excipient substance through conventional granule technology.

The specific embodiment 2:

Get 7 parts of the Rhizoma Atractylodis Macrocephalaes, 9 parts of water vapour distillation volatile oil of Fructus Forsythiae by weight ratio, volatile oil solution adds the beta-schardinger dextrin-inclusion, separates, and low-temperature vacuum drying is subsequent use; 11 parts of Radix Notoginseng, 8 parts of Fructus Psoraleaes are subsequent use with the alcohol reflux alcohol extract with 70%; Incorporate into after 25 parts of first water of Carapax Trionycis are carried 2 hours 7 parts of 5 parts of Hirudos, 20 parts of Herba Desmodii Styracifolii, 9 parts of Fructus Forsythiaes, 8 parts of Caulis Clematidis Armandiis, Radix Cyathulae again water carry 3 times, merge the water extract, concentrate; Add 70% second ferment deposition, filter, filtrating merges with the Radix Notoginseng alcohol extract; Reclaim ethanol extract, it is subsequent use to be dried to dried cream; Dried cream and Cornu Naemorhedi powder, volatile oil inclusion complex mixed powder are broken into fine powder, the abundant mixing of medicine, and above raw material is processed capsule system with corresponding excipient substance through conventional technology.

The specific embodiment 3:

Get 5 parts of the Rhizoma Atractylodis Macrocephalaes, 10 parts of water vapour distillation volatile oil of Fructus Forsythiae by weight ratio, volatile oil solution adds the beta-schardinger dextrin-inclusion, separates, and low-temperature vacuum drying is subsequent use; 8 parts of Radix Notoginseng, 7 parts of Fructus Psoraleaes are subsequent use with the alcohol reflux alcohol extract with 70%; Incorporate into after 25 parts of first water of Carapax Trionycis are carried 2 hours 8 parts of 6 parts of Hirudos, 15 parts of Herba Desmodii Styracifolii, 10 parts of Fructus Forsythiaes, 7 parts of Caulis Clematidis Armandiis, Radix Cyathulae again water carry 3 times, merge the water extract, concentrate; Add 70% ethanol precipitation, filter, filtrating merges with the Radix Notoginseng alcohol extract; Reclaim ethanol extract, it is subsequent use to be dried to dried cream; Dried cream and Cornu Naemorhedi powder, volatile oil inclusion complex mixed powder are broken into fine powder, the abundant mixing of medicine, and above raw material is processed tablet with corresponding excipient substance through conventional technology.

The specific embodiment 4:

Get 3 parts of the Rhizoma Atractylodis Macrocephalaes, 5 parts of water vapour distillation volatile oil of Fructus Forsythiae by weight ratio, volatile oil solution adds the beta-schardinger dextrin-inclusion, separates, and low-temperature vacuum drying is subsequent use; 13 parts of Radix Notoginseng, 5 parts of Fructus Psoraleaes are subsequent use with the alcohol reflux alcohol extract with 70%; Incorporate into after 17 parts of first water of Carapax Trionycis are carried 2 hours 6 parts of 5 parts of Hirudos, 22 parts of Herba Desmodii Styracifolii, 8 parts of Fructus Forsythiaes, 4 parts of Caulis Clematidis Armandiis, Radix Cyathulae again water carry 3 times, merge the water extract, concentrate; Add 70% ethanol precipitation, filter, filtrating merges with the Radix Notoginseng alcohol extract; Reclaim ethanol extract, it is subsequent use to be dried to dried cream; Dried cream and Cornu Naemorhedi powder, volatile oil inclusion complex mixed powder are broken into fine powder, the abundant mixing of medicine, and above raw material is processed pill through conventional pill technology.

Claims

1. medicine that is used to treat prostatitis, benign prostatic hyperplasia is characterized in that the serve as reasons crude drug of following weight ratio of described medicine processes: Radix Notoginseng 7-14, Hirudo 3-9, Cornu Naemorhedi powder 2-6, Fructus Psoraleae 3-9, Herba Desmodii Styracifolii 10-25, Caulis Clematidis Armandii 3-9, Fructus Forsythiae 3-12, Carapax Trionycis 10-30, Rhizoma Atractylodis Macrocephalae 2-8, Radix Cyathulae 3-10.